Literature DB >> 23568447

Peripelvic/periureteral fat invasion is independently associated with worse prognosis in pT3 upper tract urothelial carcinoma.

Jinsung Park1, Sejun Park, Cheryn Song, Jun Hyuk Hong, Choung-Soo Kim, Hanjong Ahn.   

Abstract

PURPOSE: To elucidate the reasons for conflicting results regarding the prognostic significance of tumor location in upper tract urothelial carcinoma (UTUC), we analyzed the stage-specific impact of tumor location on oncological outcomes following radical nephroureterectomy (RNU).
METHODS: Data from 392 patients who underwent RNU with curative intent between 1991 and 2010 were reviewed. Prognostic impact of tumor location and various clinicopathological factors for recurrence-free survival (RFS) and cancer-specific survival (CSS) was evaluated using Kaplan-Meier and Cox regression analyses at each pathological stage. Tumor location was classified as renal pelvis or ureter, and pT3 tumors were further stratified as invading the renal parenchyma or peripelvic or periureteral fat.
RESULTS: In stage-specific analysis, tumor location did not have prognostic significance in patients with ≤pT2 tumors, whereas RFS and CSS rates were significantly lower in patients with pT3 ureteral tumors than renal pelvic tumors. Subgroup analysis showed that RFS and CSS rates were significantly higher for pT3 tumors invading the renal parenchyma than the peripelvic or periureteral fat. On multivariate analysis in pT3 tumors adjusting other clinicopathological parameters, tumor location remained significant predictors for both RFS and CSS. Compared with tumors invading renal parenchyma, tumors invading peripelvic fat or periureteral fat were associated with about 3.5 times higher risk for cancer-specific mortality (p < 0.05).
CONCLUSIONS: Location-dependent survival difference exists only in patients with pT3 UTUC. Conflicting institutional results regarding tumor location in UTUC may be due to difference in the proportions of parenchymal versus peripelvic fat invasion in pT3 pelvic tumors.

Entities:  

Mesh:

Year:  2013        PMID: 23568447     DOI: 10.1007/s00345-013-1073-8

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  30 in total

Review 1.  Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature.

Authors:  Giovanni Lughezzani; Maximilian Burger; Vitaly Margulis; Surena F Matin; Giacomo Novara; Morgan Roupret; Shahrokh F Shariat; Christopher G Wood; Richard Zigeuner
Journal:  Eur Urol       Date:  2012-02-23       Impact factor: 20.096

Review 2.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

3.  Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery.

Authors:  Michael Rink; Behfar Ehdaie; Eugene K Cha; David A Green; Pierre I Karakiewicz; Marko Babjuk; Vitaly Margulis; Jay D Raman; Robert S Svatek; Harun Fajkovic; Richard K Lee; Giacomo Novara; Jens Hansen; Siamak Daneshmand; Yair Lotan; Wassim Kassouf; Hans-Martin Fritsche; Armin Pycha; Margit Fisch; Douglas S Scherr; Shahrokh F Shariat
Journal:  Eur Urol       Date:  2012-02-15       Impact factor: 20.096

Review 4.  Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification.

Authors:  Anirban P Mitra; Ram H Datar; Richard J Cote
Journal:  J Clin Oncol       Date:  2006-12-10       Impact factor: 44.544

5.  Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients.

Authors:  Wolfgang Otto; Shahrokh F Shariat; Hans-Martin Fritsche; Amit Gupta; Kazumasa Matsumoto; Wassim Kassouf; Guido Martignoni; Thomas J Walton; Stefan Tritschler; Shiro Baba; Patrick J Bastian; Juan I Martínez-Salamanca; Christian Seitz; Armin Pycha; Maximilian Burger; Pierre I Karakiewicz; Vincenzo Ficarra; Giacomo Novara
Journal:  World J Urol       Date:  2011-01-20       Impact factor: 4.226

6.  Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.

Authors:  James W F Catto; Abdel-Rahmene Azzouzi; Ishtiaq Rehman; Kenneth M Feeley; Simon S Cross; Najla Amira; Gaelle Fromont; Mathilde Sibony; Oliver Cussenot; Mark Meuth; Freddie C Hamdy
Journal:  J Clin Oncol       Date:  2005-03-07       Impact factor: 44.544

7.  Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients.

Authors:  Mesut Remzi; Andrea Haitel; Vitaly Margulis; Pierre Karakiewicz; Pierre Karakiewizc; Francesco Montorsi; Eiji Kikuchi; Richard Zigeuner; Alon Weizer; Christian Bolenz; Karim Bensalah; Nazareno Suardi; Jay D Raman; Yair Lotan; Matthias Waldert; Casey K Ng; Mario Fernández; Theresa M Koppie; Philipp Ströbel; Wareef Kabbani; Masaru Murai; Cord Langner; Marco Roscigno; Jeffrey Wheat; Charles C Guo; Christopher G Wood; Shahrokh F Shariat
Journal:  BJU Int       Date:  2008-10-16       Impact factor: 5.588

8.  The protective role of renal parenchyma as a barrier to local tumor spread of upper tract transitional cell carcinoma and its impact on patient survival.

Authors:  Jinsung Park; Seong Heon Ha; Gyeng Eun Min; Cheryn Song; Bumsik Hong; Jun Hyuk Hong; Choung-Soo Kim; Hanjong Ahn
Journal:  J Urol       Date:  2009-07-17       Impact factor: 7.450

9.  Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers.

Authors:  Giacomo Novara; Vincenzo De Marco; Fedra Gottardo; Orietta Dalpiaz; Vianney Bouygues; Antonio Galfano; Guido Martignoni; Jean Jacques Patard; Walter Artibani; Vincenzo Ficarra
Journal:  Cancer       Date:  2007-10-15       Impact factor: 6.860

10.  Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma: proposal and multi-institutional validation of a post-operative nomogram.

Authors:  D R Yates; V Hupertan; P Colin; A Ouzzane; A Descazeaud; J A Long; G Pignot; S Crouzet; F Rozet; Y Neuzillet; M Soulie; T Bodin; A Valeri; O Cussenot; M Rouprêt
Journal:  Br J Cancer       Date:  2012-02-28       Impact factor: 7.640

View more
  5 in total

Review 1.  Association between demographic factors and prognosis in urothelial carcinoma of the upper urinary tract: a systematic review and meta-analysis.

Authors:  Hyung Suk Kim; Chang Wook Jeong; Cheol Kwak; Hyeon Hoe Kim; Ja Hyeon Ku
Journal:  Oncotarget       Date:  2017-01-31

Review 2.  Why are upper tract urothelial carcinoma two different diseases?

Authors:  Tibor Szarvas; Orsolya Módos; András Horváth; Péter Nyirády
Journal:  Transl Androl Urol       Date:  2016-10

3.  The effectiveness of chemotherapy for patients with pT3N0M0 renal pelvic urothelial carcinomas: An inverse probability of treatment weighting comparison using Surveillance, Epidemiology, and End Results data.

Authors:  Zefu Liu; Jialing Huang; Xiangdong Li; Chaowen Huang; Yunlin Ye; Jinxin Zhang; Zhouwei Liu
Journal:  Cancer Med       Date:  2020-06-25       Impact factor: 4.452

4.  The Prognostic Impact of Tumor Location in pT3N0M0 Upper Urinary Tract Urothelial Carcinoma: A Retrospective Cohort Study.

Authors:  Tzu Shuang Chen; Yen Ta Chen; Hung Jen Wang; Po Hui Chiang; Wen Chou Yang; Wei Ching Lee; Yao Chi Chuang; Yuan Tso Cheng; Chih Hsiung Kang; Wei Chia Lee; Chien Hsu Chen; Yuan Chi Shen; Yi Yang Liu; Hui Ying Liu; Yin Lun Chang; Yu Li Su; Chun Chieh Huang; Hao Lun Luo
Journal:  Front Oncol       Date:  2022-03-15       Impact factor: 6.244

5.  The prognostic value of tumor architecture in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: A systematic review and meta-analysis.

Authors:  Hu Zhao; Lijin Zhang; Bin Wu; Zhenlei Zha; Jun Yuan; Yuefang Jiang; Yejun Feng
Journal:  Medicine (Baltimore)       Date:  2020-09-11       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.